https://media-us.eisai.com/ Eisai Newsroom https://media-us.eisai.com/2026-05-20-Eisai-Deepens-Body-of-Clinical-Evidence-for-LENVIMA-Lenvatinib-Across-Established-Indications-at-ASCO-2026 Wed, 20 May 2026 08:08:00 -0400 https://media-us.eisai.com/2026-05-20-Eisai-Deepens-Body-of-Clinical-Evidence-for-LENVIMA-Lenvatinib-Across-Established-Indications-at-ASCO-2026 https://media-us.eisai.com/2026-04-10-New-Survey-Data-Exploring-Patient-Experiences-with-Endometrial-Cancer-Care-Presented-at-2026-Society-of-Gynecologic-Oncology-SGO-Annual-Meeting-on-Womens-Cancer Fri, 10 Apr 2026 07:00:00 -0400 https://media-us.eisai.com/2026-04-10-New-Survey-Data-Exploring-Patient-Experiences-with-Endometrial-Cancer-Care-Presented-at-2026-Society-of-Gynecologic-Oncology-SGO-Annual-Meeting-on-Womens-Cancer https://media-us.eisai.com/2026-02-26-Eisai-and-Advocacy-Leaders-Launch-Kompass,-a-Digital-Destination-to-Help-Patients-and-Caregivers-Navigate-the-Complexities-of-Kidney-Cancer Thu, 26 Feb 2026 08:08:00 -0500 https://media-us.eisai.com/2026-02-26-Eisai-and-Advocacy-Leaders-Launch-Kompass,-a-Digital-Destination-to-Help-Patients-and-Caregivers-Navigate-the-Complexities-of-Kidney-Cancer https://media-us.eisai.com/2025-11-03-Eisai-Demonstrates-Commitment-to-Advanced-Endometrial-Cancer-Care-at-IGCS-2025 Mon, 03 Nov 2025 08:08:00 -0500 https://media-us.eisai.com/2025-11-03-Eisai-Demonstrates-Commitment-to-Advanced-Endometrial-Cancer-Care-at-IGCS-2025 https://media-us.eisai.com/2025-10-02-Eisai-Highlights-Breadth-of-Oncology-Research-at-ESMO-2025,-Featuring-5-Year-Survival-Data-from-Study-309-KEYNOTE-775 Thu, 02 Oct 2025 08:08:00 -0400 https://media-us.eisai.com/2025-10-02-Eisai-Highlights-Breadth-of-Oncology-Research-at-ESMO-2025,-Featuring-5-Year-Survival-Data-from-Study-309-KEYNOTE-775 https://media-us.eisai.com/2025-05-20-Eisai-Demonstrates-Commitment-to-Oncology-Innovation-at-ASCO-2025 Tue, 20 May 2025 08:08:00 -0400 https://media-us.eisai.com/2025-05-20-Eisai-Demonstrates-Commitment-to-Oncology-Innovation-at-ASCO-2025 https://media-us.eisai.com/2024-09-14-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-in-Combination-With-Transarterial-Chemoembolization-TACE-Significantly-Improved-Progression-Free-Survival-Compared-to-TACE-Alone-in-Patients-With-Unresectable,-Non-Metastatic-Hepatocellular-Car Sat, 14 Sep 2024 11:26:00 -0400 https://media-us.eisai.com/2024-09-14-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-in-Combination-With-Transarterial-Chemoembolization-TACE-Significantly-Improved-Progression-Free-Survival-Compared-to-TACE-Alone-in-Patients-With-Unresectable,-Non-Metastatic-Hepatocellular-Car https://media-us.eisai.com/2024-09-04-Eisai-Accelerates-Progress-in-Oncology-Research-with-New-Data-at-ESMO-Congress-2024,-Including-First-Interim-Analysis-Results-from-the-Phase-3-LEAP-012-Trial Wed, 04 Sep 2024 08:08:00 -0400 https://media-us.eisai.com/2024-09-04-Eisai-Accelerates-Progress-in-Oncology-Research-with-New-Data-at-ESMO-Congress-2024,-Including-First-Interim-Analysis-Results-from-the-Phase-3-LEAP-012-Trial https://media-us.eisai.com/2024-06-27-New-Efficacy-Data-for-Non-Clear-Cell-Renal-Cell-Carcinoma-From-KEYNOTE-B61-Added-to-LENVIMA-R-lenvatinib-US-Label-Supporting-KEYTRUDA-LENVIMA-Indication-for-the-First-Line-Treatment-of-Adult-Patients-With-Advanced-RCC Thu, 27 Jun 2024 16:35:00 -0400 https://media-us.eisai.com/2024-06-27-New-Efficacy-Data-for-Non-Clear-Cell-Renal-Cell-Carcinoma-From-KEYNOTE-B61-Added-to-LENVIMA-R-lenvatinib-US-Label-Supporting-KEYTRUDA-LENVIMA-Indication-for-the-First-Line-Treatment-of-Adult-Patients-With-Advanced-RCC https://media-us.eisai.com/2024-06-27-New-Post-Hoc-Analysis-from-Phase-3-REFLECT-Trial-Presented-at-ESMO-GI-2024-Explores-Efficacy-Outcomes-with-LENVIMA-R-lenvatinib-Based-on-Depth-of-Tumor-Response-in-Unresectable-Hepatocellular-Carcinoma Thu, 27 Jun 2024 09:35:00 -0400 https://media-us.eisai.com/2024-06-27-New-Post-Hoc-Analysis-from-Phase-3-REFLECT-Trial-Presented-at-ESMO-GI-2024-Explores-Efficacy-Outcomes-with-LENVIMA-R-lenvatinib-Based-on-Depth-of-Tumor-Response-in-Unresectable-Hepatocellular-Carcinoma https://media-us.eisai.com/2024-05-23-Eisai-Showcases-Oncology-Portfolio-and-Pipeline-at-ASCO-2024 Thu, 23 May 2024 08:08:00 -0400 https://media-us.eisai.com/2024-05-23-Eisai-Showcases-Oncology-Portfolio-and-Pipeline-at-ASCO-2024 https://media-us.eisai.com/2024-01-18-Eisai-Aims-to-Advance-Genitourinary-Cancer-Treatment-with-New-Research-at-ASCO-GU-2024 Thu, 18 Jan 2024 08:08:00 -0500 https://media-us.eisai.com/2024-01-18-Eisai-Aims-to-Advance-Genitourinary-Cancer-Treatment-with-New-Research-at-ASCO-GU-2024 https://media-us.eisai.com/2024-01-16-Eisai-Furthers-Oncology-Research-in-Gastrointestinal-Cancer-Treatment-with-New-Data-at-ASCO-GI-2024 Tue, 16 Jan 2024 08:08:00 -0500 https://media-us.eisai.com/2024-01-16-Eisai-Furthers-Oncology-Research-in-Gastrointestinal-Cancer-Treatment-with-New-Data-at-ASCO-GI-2024 https://media-us.eisai.com/2023-10-11-Eisai-to-Present-Research-From-Oncology-Portfolio-and-Pipeline-at-ESMO-Congress-2023 Wed, 11 Oct 2023 08:08:00 -0400 https://media-us.eisai.com/2023-10-11-Eisai-to-Present-Research-From-Oncology-Portfolio-and-Pipeline-at-ESMO-Congress-2023 https://media-us.eisai.com/2023-05-23-Eisai-Delivers-New-Data-and-Highlights-Continued-Progress-of-Oncology-Portfolio-and-Pipeline-at-ASCO-2023 Tue, 23 May 2023 08:08:00 -0400 https://media-us.eisai.com/2023-05-23-Eisai-Delivers-New-Data-and-Highlights-Continued-Progress-of-Oncology-Portfolio-and-Pipeline-at-ASCO-2023 https://media-us.eisai.com/2023-04-11-EISAI-AND-PATIENT-ADVOCACY-PARTNERS-LAUNCH-MADE-OF-MORE-AN-EDUCATION-INITIATIVE-TO-SPOTLIGHT-HEAD-AND-NECK-CANCER Tue, 11 Apr 2023 08:08:00 -0400 https://media-us.eisai.com/2023-04-11-EISAI-AND-PATIENT-ADVOCACY-PARTNERS-LAUNCH-MADE-OF-MORE-AN-EDUCATION-INITIATIVE-TO-SPOTLIGHT-HEAD-AND-NECK-CANCER https://media-us.eisai.com/2023-03-23-Eisai-to-Present-Research-from-Oncology-Portfolio-at-the-Society-of-Gynecologic-Oncology-SGO-2023-Annual-Meeting-on-Womens-Cancer Thu, 23 Mar 2023 08:08:00 -0400 https://media-us.eisai.com/2023-03-23-Eisai-to-Present-Research-from-Oncology-Portfolio-at-the-Society-of-Gynecologic-Oncology-SGO-2023-Annual-Meeting-on-Womens-Cancer https://media-us.eisai.com/2023-01-18-Eisai-Aims-to-Advance-Gastrointestinal-Cancer-Treatment-with-Research-Across-Multiple-Tumor-Types-at-ASCO-GI-2023 Wed, 18 Jan 2023 08:08:00 -0500 https://media-us.eisai.com/2023-01-18-Eisai-Aims-to-Advance-Gastrointestinal-Cancer-Treatment-with-Research-Across-Multiple-Tumor-Types-at-ASCO-GI-2023 https://media-us.eisai.com/2022-12-01-Eisai-to-Present-Preclinical-and-Clinical-Research-on-Eribulin-at-the-2022-San-Antonio-Breast-Cancer-Symposium Thu, 01 Dec 2022 08:08:00 -0500 https://media-us.eisai.com/2022-12-01-Eisai-to-Present-Preclinical-and-Clinical-Research-on-Eribulin-at-the-2022-San-Antonio-Breast-Cancer-Symposium https://media-us.eisai.com/2022-10-21-Eisai-Announces-Real-World-Evidence-on-the-Clinical-Effectiveness-of-LENVIMA-R-lenvatinib-Monotherapy-for-the-Treatment-of-Patients-with-Radioiodine-Refractory-Differentiated-Thyroid-Cancer Fri, 21 Oct 2022 10:30:00 -0400 https://media-us.eisai.com/2022-10-21-Eisai-Announces-Real-World-Evidence-on-the-Clinical-Effectiveness-of-LENVIMA-R-lenvatinib-Monotherapy-for-the-Treatment-of-Patients-with-Radioiodine-Refractory-Differentiated-Thyroid-Cancer https://media-us.eisai.com/Merck-and-Eisai-Present-Results-From-Phase-3-LEAP-002-Trial-Evaluating-KEYTRUDA-pembrolizumab-Plus-LENVIMA-lenvatinib-Versus-LENVIMA-Monotherapy-in-Patients-With-Unresectable-Hepatocellular-Carcinoma Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022 Sat, 10 Sep 2022 08:33:00 -0400 https://media-us.eisai.com/Merck-and-Eisai-Present-Results-From-Phase-3-LEAP-002-Trial-Evaluating-KEYTRUDA-pembrolizumab-Plus-LENVIMA-lenvatinib-Versus-LENVIMA-Monotherapy-in-Patients-With-Unresectable-Hepatocellular-Carcinoma https://media-us.eisai.com/2022-09-10-Eisai-Presents-Results-of-Post-Hoc-Analysis-of-Eribulin-Mesylate-HALAVEN-R-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2022 Sat, 10 Sep 2022 05:20:00 -0400 https://media-us.eisai.com/2022-09-10-Eisai-Presents-Results-of-Post-Hoc-Analysis-of-Eribulin-Mesylate-HALAVEN-R-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2022 https://media-us.eisai.com/2022-09-06-Eisai-Presents-New-Data-From-its-Oncology-Portfolio-and-Pipeline-at-ESMO-Congress-2022 Tue, 06 Sep 2022 08:08:00 -0400 https://media-us.eisai.com/2022-09-06-Eisai-Presents-New-Data-From-its-Oncology-Portfolio-and-Pipeline-at-ESMO-Congress-2022 https://media-us.eisai.com/2022-08-04-BASEBALL-LEGEND-BERNIE-WILLIAMS-TEAMS-UP-WITH-EISAI-AND-ADVOCACY-PARTNERS-TO-LAUNCH-ONE-LIVER-TO-LOVE-INITIATIVE-TO-HELP-RAISE-AWARENESS-ABOUT-LIVER-CANCER-AND-THE-IMPORTANCE-OF-LIVER-HEALTH Thu, 04 Aug 2022 08:08:00 -0400 https://media-us.eisai.com/2022-08-04-BASEBALL-LEGEND-BERNIE-WILLIAMS-TEAMS-UP-WITH-EISAI-AND-ADVOCACY-PARTNERS-TO-LAUNCH-ONE-LIVER-TO-LOVE-INITIATIVE-TO-HELP-RAISE-AWARENESS-ABOUT-LIVER-CANCER-AND-THE-IMPORTANCE-OF-LIVER-HEALTH https://media-us.eisai.com/Merck-and-Eisai-Provide-Update-on-Phase-3-LEAP-002-Trial-Evaluating-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-Versus-LENVIMA-Monotherapy-in-Patients-With-Unresectable-Hepatocellular-Carcinoma Wed, 03 Aug 2022 07:38:00 -0400 https://media-us.eisai.com/Merck-and-Eisai-Provide-Update-on-Phase-3-LEAP-002-Trial-Evaluating-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-Versus-LENVIMA-Monotherapy-in-Patients-With-Unresectable-Hepatocellular-Carcinoma